Sex differences in response to intranasal oxytocin as an adjunctive therapy for patients with severe mental illness.

Autor: Maoz H; Shalvata Mental Health Center, Affiliated with the School of Medicine, Tel-Aviv University, Tel-Aviv-Jaffa, Israel; School of Medicine, Tel-Aviv University, Tel-Aviv-Jaffa, Israel. Electronic address: hagai.maoz@moh.gov.il., Grossman-Giron A; Shalvata Mental Health Center, Affiliated with the School of Medicine, Tel-Aviv University, Tel-Aviv-Jaffa, Israel; Department of Behavioral Sciences, Ariel University, Ariel, Israel., Baruch N; Department of Behavioral Sciences, Ariel University, Ariel, Israel., Sedoff O; Shalvata Mental Health Center, Affiliated with the School of Medicine, Tel-Aviv University, Tel-Aviv-Jaffa, Israel; Department of Community Mental Health, University of Haifa, Haifa, Israel., Mama Y; Department of Behavioral Sciences, Ariel University, Ariel, Israel., Nitzan U; Shalvata Mental Health Center, Affiliated with the School of Medicine, Tel-Aviv University, Tel-Aviv-Jaffa, Israel; School of Medicine, Tel-Aviv University, Tel-Aviv-Jaffa, Israel., Tzur Bitan D; Shalvata Mental Health Center, Affiliated with the School of Medicine, Tel-Aviv University, Tel-Aviv-Jaffa, Israel; Department of Community Mental Health, University of Haifa, Haifa, Israel.
Jazyk: angličtina
Zdroj: Psychiatry research [Psychiatry Res] 2024 Dec; Vol. 342, pp. 116269. Date of Electronic Publication: 2024 Nov 14.
DOI: 10.1016/j.psychres.2024.116269
Abstrakt: Studies investigating the potential benefits of intranasal oxytocin (INOT) as an add-on treatment for patients with severe mental illness (SMI) have yielded inconsistent results, potentially due to sex differences in response to INOT. This study explored the differential effects of INOT among male and female patients with SMI. A secondary analysis was conducted on a previously studied group of patients who participated in a double-blind, placebo-controlled trial evaluating the impact of INOT as an add-on treatment for patients with SMI. Patients treated in inpatient settings (N = 87) received twice-daily INOT (32IU) or placebo (PLC) for a period of four weeks. Sex moderated the effect of OT/PLC on the Hamilton Rating Scale for Depression (HRDS) (p < 0.001). A significant effect for sex was found in the Hopkins Symptom Checklist-short form (HSCL-11) (p = 0.04) and HRDS (p < 0.001), with females showing greater reductions in anxiety and depression symptoms and severity. This effect was not found for males. We conclude that the addition of INOT to the treatment of patients with SMI in an inpatient setting was beneficial for female patients, particularly reducing depressive symptoms, but not for male patients. Future studies should aim to identify patients who are more likely to benefit from INOT administration.
Competing Interests: Declaration of competing interest The authors of this manuscript have no conflict of interest to declare regarding this manuscript. Other financial relations are as follows: Prof. Dana Tzur Bitan received a research grant from Pfizer and from the American Psychological Foundation. All other authors report no financial relationships with commercial interests.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: